NASDAQ: BNOX - Bionomics Limited

Rentabilité sur six mois: -49.58%
Secteur: Healthcare

Calendrier des promotions Bionomics Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

plus de détails
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2021-12-16
ISIN US09063M2052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.bionomics.com.au
Цена ао 0.278
Changement de prix par jour: -9.44% (4.45)
Changement de prix par semaine: +38.26% (2.9148)
Changement de prix par mois: +12.7% (3.576)
Changement de prix sur 3 mois: -47.51% (7.6776)
Changement de prix sur six mois: -49.58% (7.9932)
Changement de prix par an: +172.3% (1.48)
Evolution du prix sur 3 ans: -68.64% (12.85)
Evolution du prix sur 5 ans: 0% (4.03)
Evolution des prix sur 10 ans: 0% (4.03)
Evolution des prix depuis le début de l'année: +20.33% (3.3492)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 4290.29 1
P/BV 4.91 3
P/E 0 0
EV/EBITDA -7.47 0
Total: 2.75

Efficacité

Nom Signification Grade
ROA, % -66284.99 0
ROE, % -117366.73 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.027 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -99.32 0
Rentabilité Ebitda, % -88.49 0
Rentabilité EPS, % 2304445.45 10
Total: 4
Plus de détails

Établissements Volume Partager, %
Lynx1 Capital Management Lp 824305 10.1
Point72 Asset Management, L.P. 331000 4.06
Morgan Stanley 94967 1.16
Two Sigma Investments, LP 31272 0.38
XTX Topco Ltd 11834 0.15
Tower Research Capital LLC (TRC) 1606 0.02
Rhumbline Advisers 505 0.01
UBS Group AG 329 0
Aspire Private Capital, LLC 200 0



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 510.37k 1973 (52 année)
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer N/A 1963 (62 année)
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations N/A
Ms. Elizabeth Doolin Senior Vice President of Clinical Development 1965 (60 années)
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 1955 (70 années)

Adresse: Australia, Eastwood, 200 Greenhill Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.bionomics.com.au